In another recent study using APRIL-based, 2nd generation CAR that targets BCMA and TACI simultaneously, it was further shown that APRIL in a trimeric format (Tr-iAPRIL) as the antigen-binding domain, displayed enhanced binding to BCMA and TACI and exhibited greater target cytolysis activity against MM compared to monomeric APRIL CAR [85]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.